Drug Trial Radar · NCT05901935
DP303c in Patients With HER2-positive Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jun 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
420
Planned (sponsor's estimate)
Start
Jul 2023
Primary completion
Jan 2026
Study completion Jul 2028
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study of DP303c in patients with HER2-positive advanced breast cancer.
Conditions
- HER2-positive Advanced Breast Cancer
Interventions
DP303cDrug
DP303c injection, 3.0 mg/kg, Q3W.
TrastuzumabDrug
IV, 6 mg/kg, D1, Q3W
Vinorelbine TartrateDrug
IV, 25 mg/m\^2,D1、D8,Q3W
Capecitabine tabletsDrug
PO 1000 mg/m\^2, bid, D1-D14, Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) by BIRCTime frame: Up to approximately 5 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.